Steven Kok Foung

Title: The Innovations of Steven Kok Foung

Introduction

Steven Kok Foung is a notable inventor based in Stanford, California. He has made significant contributions to the field of biotechnology, particularly in the study of human T-cell lymphotropic virus type I (HTLV-I). His work has implications for the diagnosis and understanding of viral infections.

Latest Patents

Steven Kok Foung holds a patent for the isolated and purified envelope protein of HTLV-I. This invention provides a recombinant form of the envelope protein, produced using a dual vaccinia/T7 polymerase system. The protein is available in both non-glycosylated and glycosylated forms, with the latter being recognized by specific antibodies. His patent also includes monoclonal antibodies that are specific for the HTLV-I envelope protein, which do not bind to the denatured form of the protein. This innovation is crucial for diagnosing infections caused by HTLV-I and HTLV-II.

Career Highlights

Throughout his career, Steven Kok Foung has worked with prestigious institutions, including Leland Stanford Junior University and The University of Western Ontario. His research has focused on the development of diagnostic tools and therapeutic strategies related to viral infections.

Collaborations

Steven has collaborated with notable colleagues such as Jacqueline Arp and Gregory A Dekaban. Their combined expertise has contributed to advancements in the understanding of HTLV-I and its implications for human health.

Conclusion

Steven Kok Foung's innovative work in the field of biotechnology has led to significant advancements in the diagnosis of viral infections. His contributions continue to impact the scientific community and enhance our understanding of HTLV-I.